tradingkey.logo

Drugs Made In America Acquisition Corp

DMAA
10.380USD
+0.020+0.19%
Market hours ETQuotes delayed by 15 min
347.89MMarket Cap
94.62P/E TTM

Drugs Made In America Acquisition Corp

10.380
+0.020+0.19%

More Details of Drugs Made In America Acquisition Corp Company

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.

Drugs Made In America Acquisition Corp Info

Ticker SymbolDMAA
Company nameDrugs Made In America Acquisition Corp
IPO dateJan 28, 2025
CEOStockwell (Lynn)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJan 28
Address1 East Broward Boulevard
CityFT LAUDERDALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33301
Phone19548703099
Website
Ticker SymbolDMAA
IPO dateJan 28, 2025
CEOStockwell (Lynn)

Company Executives of Drugs Made In America Acquisition Corp

Name
Name/Position
Position
Shareholding
Change
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Drugs Made In America Acquisition LLC
25.57%
Karpus Investment Management
7.60%
First Trust Capital Management L.P.
6.69%
Polar Asset Management Partners Inc.
5.67%
Glazer Capital, LLC
5.44%
Other
49.03%
Shareholders
Shareholders
Proportion
Drugs Made In America Acquisition LLC
25.57%
Karpus Investment Management
7.60%
First Trust Capital Management L.P.
6.69%
Polar Asset Management Partners Inc.
5.67%
Glazer Capital, LLC
5.44%
Other
49.03%
Shareholder Types
Shareholders
Proportion
Hedge Fund
30.25%
Corporation
25.57%
Investment Advisor/Hedge Fund
24.75%
Investment Advisor
5.74%
Research Firm
5.62%
Individual Investor
1.19%
Other
6.88%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
47
22.21M
67.76%
-8.45K
2025Q3
47
22.22M
67.76%
+1.02M
2025Q2
38
21.21M
54.90%
+2.81M
2025Q1
25
18.33M
0.00%
+18.33M
2024Q4
5
4.59M
15.73%
+4.59M

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Drugs Made In America Acquisition LLC
8.57M
25.57%
+4.38M
+104.63%
Feb 25, 2025
Karpus Investment Management
2.74M
8.19%
+420.07K
+18.08%
Jun 30, 2025
First Trust Capital Management L.P.
2.24M
6.69%
+175.80K
+8.51%
Jun 30, 2025
Polar Asset Management Partners Inc.
1.90M
5.67%
--
--
Jun 30, 2025
Glazer Capital, LLC
1.82M
5.44%
-502.00
-0.03%
Jun 30, 2025
Westchester Capital Management, LLC
1.67M
4.98%
+690.00K
+70.48%
Jun 30, 2025
Hudson Bay Capital Management LP
1.80M
5.37%
--
--
Jun 30, 2025
Wolverine Asset Management, LLC
1.02M
3.05%
+418.87K
+69.46%
Jun 30, 2025
Mizuho Securities USA, LLC.
919.79K
2.74%
+919.79K
--
Jun 30, 2025
Aristeia Capital, L.L.C.
881.72K
2.63%
-18.28K
-2.03%
Jun 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
CrossingBridge Pre-Merger SPAC ETF
0%
CrossingBridge Pre-Merger SPAC ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data

FAQs

Who are the top five shareholders of Drugs Made In America Acquisition Corp?

The top five shareholders of Drugs Made In America Acquisition Corp are:
Drugs Made In America Acquisition LLC holds 8.57M shares, accounting for 25.57% of the total shares.
Karpus Investment Management holds 2.74M shares, accounting for 8.19% of the total shares.
First Trust Capital Management L.P. holds 2.24M shares, accounting for 6.69% of the total shares.
Polar Asset Management Partners Inc. holds 1.90M shares, accounting for 5.67% of the total shares.
Glazer Capital, LLC holds 1.82M shares, accounting for 5.44% of the total shares.

What are the top three shareholder types of Drugs Made In America Acquisition Corp?

The top three shareholder types of Drugs Made In America Acquisition Corp are:
Drugs Made In America Acquisition LLC
Karpus Investment Management
First Trust Capital Management L.P.

How many institutions hold shares of Drugs Made In America Acquisition Corp (DMAA)?

As of 2025Q4, 47 institutions hold shares of Drugs Made In America Acquisition Corp, with a combined market value of approximately 22.21M, accounting for 67.76% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.

What is the biggest source of revenue for Drugs Made In America Acquisition Corp?

In --, the -- business generated the highest revenue for Drugs Made In America Acquisition Corp, amounting to -- and accounting for --% of total revenue.
KeyAI